Zhi-Qiang Chen

Title: Zhi-Qiang Chen: Innovator in Ischemia Treatment

Introduction

Zhi-Qiang Chen is a prominent inventor based in Houston, TX (US). He has made significant contributions to the field of medicine, particularly in the treatment of ischemia. His innovative work has led to the development of a unique patent that addresses critical health issues.

Latest Patents

Zhi-Qiang Chen holds a patent for "Mesodermal-like cell population for treating ischemia in mammals." This patent involves compositions containing an effective amount of mesodermal-like multipotent mammalian mononuclear cells that express both CD34 and M-cadherin cell surface markers. These compositions are utilized for preventing, treating, or reducing the severity of tissue ischemia or ischemia-associated disorders in mammals. The patent outlines methods for repopulating an in vivo site with new myocytes and vascularizing ischemic or adjacent tissue. Additionally, the detection of CD34/M-cadherin mesodermal-like precursor cells in mammalian tissue samples is employed to diagnose the need for transplantation of these cells to ischemic sites.

Career Highlights

Zhi-Qiang Chen is affiliated with the University of Texas System, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on medical treatments and patient outcomes.

Collaborations

Zhi-Qiang Chen has collaborated with notable colleagues, including Pierre Zoldhelyi and James T Willerson. These partnerships have contributed to the development and refinement of his innovative approaches to treating ischemia.

Conclusion

Zhi-Qiang Chen's contributions to the field of ischemia treatment through his patent and research at the University of Texas System highlight his role as a key innovator in medical science. His work promises to enhance therapeutic options for patients suffering from ischemic conditions.